Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280404 | 1.00 | SLC2A1 (0.56) | SLC2A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6035606 | 0.92 | MEN1 (0.60) | SLC2A1NPC1RAB9ASMN1; SMN2MRGPRX4 | |
| SCHEMBL698056 | 0.90 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL3239903 | 0.90 | BCHE (0.60) | NPC1RAB9ASMN1; SMN2HTTHSD17B10 | |
| SCHEMBL31361425 | 0.90 | BCHE (0.60) | NPC1RAB9ASMN1; SMN2HTTHSD17B10 | |
| SCHEMBL31725848 | 0.90 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL13448174 | 0.87 | SLC2A1 (0.54) | SLC2A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6044557 | 0.87 | MTNR1A (0.47) | SLC2A1NPC1RAB9AHSD17B10POLB | |
| SCHEMBL31040308 | 0.86 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL30027542 | 0.86 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444569-A | Triphenylhydroxytyrosol and synthesis method thereof and application of triphenylhydroxytyrosol in preparation of medicines for improving aortic endothelial cell functions | 西安交通大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-115850334-A | Triphenylphosphonium-hydroxytyrosol, synthesis method thereof and application thereof in preparing drugs for inhibiting cancer cell proliferation | 西安交通大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2417119-B1 | NO-CARRIER-ADDED NUCLEOPHILIC ÝF-18¨FLUORINATION OF AROMATIC COMPOUNDS | UNIV CALIFORNIA (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| US-8742139-B2 | No-carrier-added nucleophilic [F-18] fluorination of aromatic compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-03 | — | — | US | disclosed |
| WO-2013062762-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-20030186943-A1 | Substituted gamma-phenyl-delta-lactams and uses related thereto | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2003-10-02 | — | — | US | disclosed |
| US-6555572-B2 | Reducing the vomiting side effects of phosphodiesterase inhibitors, e.g. Rolipram, Ariflo, by benzylation by benzyl bromide or a derivative | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2003-04-29 | — | — | US | disclosed |
| EP-1265861-A2 | BENZYLATED PDE4 INHIBITORS | Inflazyme Pharmaceuticals, Ltd. (CA) | 2002-12-18 | — | — | EP | disclosed |
| US-6458829-B1 | OR LACTAMS THEY MAY BE FORMULATED INTO PHARMACEUTICAL COMPOSITIONS, AND/OR USED IN THE TREATMENT OR PREVENTION OF INFLAMMATION | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2002-10-01 | — | — | US | disclosed |
| US-20020028842-A1 | Benzylated PDE4 inhibitors | BIOLIPOX AB (SE) | 2002-03-07 | — | — | US | disclosed |
| WO-2001068600-A2 | BENZYLATED PDE4 INHIBITORS | INFLAZYME PHARMACEUTICALS LIMITED (CA) | 2001-09-20 | — | — | WO | disclosed |
| EP-1112262-A1 | SUBSTITUTED $g(g)-PHENYL-$g(D)-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO | Inflazyme Pharmaceuticals, Ltd. (CA) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000014083-A1 | SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2000-03-16 | — | — | WO | disclosed |
| US-4218479-A | Novel benzylalcohols and pharmaceutical compositions and use thereof | TANABE SEIYAKU CO., LTD. (JP) | 1980-08-19 | — | — | US | disclosed |
| US-4131686-A | ANTIDIABETIC | TANABE SEIYAKU CO., LTD. (JP) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186943-A1 | Substituted gamma-phenyl-delta-lactams and uses related thereto | DDO, GLA, PIGO | SLC2A1 3392/4885NPC1 2914/4885RAB9A 2685/4885 |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | SNCA, PARK7, APP | SLC2A1 3428/4885NPC1 253/4885RAB9A 318/4885 |
| US-20020028842-A1 | Benzylated PDE4 inhibitors | PDE4B, PDE4A, PDE3B | SLC2A1 3058/4885NPC1 3724/4885RAB9A 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.